ReviewQuantitative imaging in medicine and surgery2026
Clinical and imaging manifestations of metastases from rare sites.
Review in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Because various primary cancers may metastasize to rare sites, metastatic tumors have a wide variety of imaging presentations. Their imaging appearance primarily depends on features related to the primary tumor, such as the degree of tumor differentiation, histopathologic category, tumor markers, and intratumor alterations. In certain clinical situations, imaging features and clinical history may help provide a more accurate diagnosis. Metastatic tumors can involve almost any organ, but the recognition of rare sites of metastasis is insufficient. Because clinical manifestations are heterogeneous and imaging manifestations are atypical, these metastatic tumors can easily be misdiagnosed or missed. Radiology plays an important role in the diagnosis and follow-up of patients with metastatic tumors. Computed tomography (CT) and magnetic resonance imaging (MRI) are the primary imaging modalities used to evaluate metastatic tumors and to differentiate metastatic tumors from other diseases (particularly primary organ tumors or inflammatory conditions). In this study, the principal clinical, histopathological, and imaging characteristics of metastases to uncommon sites were synthesized, with the dual aim of refining organ-specific differential diagnoses and providing a comprehensive overview of the variable manifestations of this rare condition. The marked morphologic heterogeneity of these metastases constitutes a formidable diagnostic challenge. The interpretation of various imaging findings plays a crucial role in the diagnosis and follow-up of patients with metastatic tumors at rare sites and may be critical to informing treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.